Master hematopoiesis for the ASCP BOC hematology exam: stem cells, developmental sites, bone marrow, spleen, and the cytokines that control blood cell production.

ASCPprep.com | Hematology

Chapter 1 โ€” HEMATOPOIESIS

ASCP Board Exam ยท Lab-Focused Study Guide
Stem Cells ยท Developmental Sites ยท Marrow & Spleen ยท Cytokines ยท Clinical Correlation ยท Practice Questions

1 ยท Priority Table & Quick Foundation

Topic Priority Why It’s Tested
Developmental sites & timeline (yolk sac โ†’ liver โ†’ marrow; embryonic Hbs) HIGH Classic recall: ‘primary site in 2nd trimester?’ and Gower/Portland vs Hb F
Adult red marrow distribution, retrogression, biopsy site, cellularity, M:E HIGH Bench-relevant: ‘best biopsy site in a 20-year-old?’ and normal M:E 3:1
HSC hierarchy & phenotype (CD34+, CD38โˆ’, Linโˆ’, HLA-DRโˆ’) HIGH Flow cytometry / stem cell enumeration questions; ‘all EXCEPT’ marker items
Erythroid progenitors (BFU-E vs CFU-E) & EPO HIGH ‘Most EPO-sensitive cell’ and EPO source (kidney) are near-guaranteed
Cytokines: early-acting vs late-acting; sources of EPO & TPO HIGH ‘All are multilineage EXCEPT IL-5’; EPO = kidney vs TPO = liver
Spleen: culling, pitting, platelet pool, hypersplenism HIGH Links to smear findings after splenectomy and pancytopenia work-ups
General morphologic changes of maturation HIGH Every lineage chapter builds on it โ€” asked directly and in cell-ID items
Receptor families & defects (ฮฒc, gp130, ฮณc โ†’ SCID; JAK2 โ†’ PV; Kostmann; EPO-R) MEDIUM Clinical-correlation questions tie receptors to diseases
Thymus & lymph node zones MEDIUM T-cell maturation (DN โ†’ DP โ†’ SP), node cortex/paracortex/medulla
Autocrine / paracrine / juxtacrine / endocrine signaling MEDIUM Definition item: membrane-bound SCF/FLT3L = juxtacrine
Negative regulators & apoptosis MEDIUM ‘All are negative regulators EXCEPT SCF’
Therapeutic cytokines & stem cell mobilization (G-CSF, plerixafor) MEDIUM Transplant/apheresis lab relevance
Microenvironment: stroma, ECM, fibronectin vs hemonectin MEDIUM Which adhesion molecule retains erythroid cells?
Historical experiments, stochastic vs instructive models, cell cycle LOW Occasional recall (Till & McCulloch, CFU-S, mitotic index)
Transcription factors, marrow circulation anatomy, liver lobule anatomy LOW Rarely tested beyond one-liners
๐ŸŽฏ KEY POINT โ€” Where to spend your time

Focus: the site timeline, adult marrow sites and cellularity, the HSC phenotype, BFU-E vs CFU-E, the EPO (kidney) / TPO (liver) split, early vs late cytokines, and spleen functions. Skim: transcription factor names, marrow vascular anatomy, and the history of stem cell experiments beyond ‘Till & McCulloch = CFU-S’.

Quick Foundation โ€” from zero

  • Blood cells are short-lived (RBC ~120 days, neutrophils ~days), so the body must replace them constantly โ€” that process is hematopoiesis.
  • Everything starts from a rare hematopoietic stem cell (HSC) that can copy itself (self-renew) and make every blood cell type (pluripotent).
  • HSCs give rise to progenitors (invisible under the microscope, named by the colonies they form: CFU-/BFU-), which give rise to maturing cells you can identify on a smear (โ€“blasts, โ€“cytes).
  • Each step narrows the cell’s options: multipotent โ†’ bipotent โ†’ unipotent โ†’ mature, non-dividing cell.
  • Growth factors (cytokines) keep progenitors alive, make them divide, and steer their lineage. Without them, cells undergo apoptosis.
  • The factory moves during development: yolk sac โ†’ liver โ†’ bone marrow. In adults it is restricted to the axial skeleton and proximal long bones.
  • The marrow is not just a container โ€” the microenvironment (niche) of stromal cells and extracellular matrix controls whether stem cells rest, renew, or differentiate.
๐Ÿ’ก Analogy

Think of a university: the HSC is the tenured professor who can train anyone and never runs out (self-renewal). Progenitors are students who have chosen a faculty (committed), and maturing cells are graduates doing the job. Cytokines are the scholarships and exam results that decide who proceeds โ€” and the campus (niche) sets the rules.

๐Ÿฅ Why this matters clinically

Every cytopenia, cytosis, leukemia, and transplant question comes back to one question: which step of this pipeline is broken, and why?

Concept Plain-English Explanation
Self-renewal A division that makes a stem cell identical to the parent โ€” keeps the pool from running out
Commitment The moment a cell ‘chooses’ a lineage; maturation then carries out that program
Progenitor (CFU/BFU) Committed but not recognizable; identified by the colony it forms in culture
Extramedullary hematopoiesis Blood-cell production outside the marrow (liver, spleen) when the marrow can’t keep up or is fibrosed
Retrogression Normal replacement of red (active) marrow by yellow (fatty) marrow with age, starting at 5โ€“7 years
Apoptosis vs necrosis Apoptosis = programmed, orderly cell death; necrosis = accidental death from injury
Pleiotropy vs redundancy Pleiotropy = one cytokine, many effects; redundancy = many cytokines, same effect

2 ยท Core Content Tables

2.1 Hematopoietic Stem Cell (HSC)

Feature Details
Definition Undifferentiated, pluripotent cell capable of self-renewal and of reconstituting the entire hematopoietic system of a lethally irradiated host
Location Bone marrow niches (endosteal/osteoblastic and vascular/perivascular); small numbers circulate in peripheral blood
Frequency ~0.5% of marrow nucleated cells (โ‰ˆ1 per 1,000 nucleated cells); only ~2 ร— 10โด HSCs per human; <5% dividing at any time (mostly G0)
Morphology Not recognizable โ€” resembles a small lymphocyte; defined functionally
Phenotype CD34+, CD38โˆ’, HLA-DRโˆ’ (low), Thy-1 low, Linโˆ’, Rhodamine-123 dull; also CD117 (c-kit / SCF-R)+ and CD110 (TPO-R)+
Why ‘Rh123 dull’ HSCs carry efflux pumps that push the dye (and drugs) out โ€” a functional marker of primitiveness
Fates Self-renewal ยท differentiation (to CLP or CMP) ยท apoptosis. Division may be symmetric (both daughters differentiate) or asymmetric (one returns to the pool)
What drives expansion (the ‘mechanism’) Physiologic need: hypoxia, blood loss, infection โ†’ cytokines (SCF, FLT3L, IL-3, TPOโ€ฆ) push quiescent HSC from G0 into cycle; loss of CD34, gain of CD38/HLA-DR = loss of ‘stemness’
Clinical significance Basis of stem cell transplantation (marrow, mobilized peripheral blood, cord blood) and gene therapy
Assay methods Flow cytometry (CD34 enumeration) ยท in-vitro colony assays (CFU-GEMM in methylcellulose; LTC-IC and HPP-CFC for primitive cells) ยท in-vivo serial transplantation into irradiated animals (true proof of HSC)
Key pitfalls CD34 is NOT HSC-specific โ€” it is also on early progenitors. A CD34 count estimates HSC + progenitor content, not pure stem cells

The HSC is rare, quiet, and invisible โ€” which is exactly why the exam tests its phenotype rather than its appearance. Acquiring CD38 and HLA-DR marks the first step away from stemness.

๐Ÿงช PRE-ANALYTICAL โ€” CD34+ cell enumeration (flow cytometry)
  • Specimen: EDTA peripheral blood, apheresis product, marrow or cord blood โ€” process promptly (viability falls with storage; follow your validated stability limit)
  • Viability dye (e.g., 7-AAD) excludes dead cells, which bind antibodies non-specifically
  • Gating: standardized ISHAGE-type sequential gating (CD45 dim, CD34+, low side scatter); single-platform counting with reference beads reduces error
  • Interference: clumps, lysed samples, and very high WBC counts in apheresis products โ€” dilute and mix well

2.2 The Three Precursor Compartments

Feature Stem Cells Progenitor Cells Maturing Cells
% of marrow precursors ~0.5% ~3% >95%
Potential Multilineage (pluripotent) Restricted: multipotent โ†’ unipotent Committed (unipotent)
Self-renewal Yes No (division tied to differentiation) No
Population behavior Stable, quiescent Amplifying (expands with demand) Amplifying, then stops dividing before full maturity
Recognizable on smear? No No Yes
How measured Functional assays in vivo / in vitro Colony assays in vitro (CFU, BFU) Morphology, differentials, M:E ratio
Naming HSC (LT-HSC, ST-HSC) CFU-GEMM, CFU-GM, BFU-E, CFU-Eโ€ฆ -blast โ†’ -cyte (e.g., pronormoblast)
Progenitor Gives Rise To Exam Note
CLP (common lymphoid progenitor) T, B, NK cells, lymphoid dendritic cells Marker: IL-7R+ (CD34+, Linโˆ’); CD10 + CD38 on committed lymphoid cells
CMP (common myeloid progenitor) All marrow myeloid lineages via CFU-GEMM IL-7Rโˆ’, SCF-R+; CD33 + CD38 on committed myeloid cells
CFU-GEMM Granulocyte, Erythrocyte, Monocyte, Megakaryocyte Equivalent of Till & McCulloch’s CFU-S
CFU-GM Neutrophils + monocytes Bipotent; CD33+, CD13+
CFU-EMk (MEP) Erythrocytes + megakaryocytes Bipotent; explains shared EPO/TPO receptor biology
BFU-E โ†’ CFU-E Pronormoblast โ†’ RBC BFU-E more primitive; CFU-E absolutely EPO-dependent
BFU-Mk โ†’ CFU-Mk Megakaryocytes โ†’ platelets TPO + IL-11 drive the largest platelet increase
CFU-Eo / CFU-Baso Eosinophils / basophils (and mast cells) Eo: IL-5; Baso: IL-3 (+ KIT ligand/IL-4)

2.3 Developmental Phases

Phase Timing Site(s) What Is Made Key Feature
Mesoblastic Begins ~day 19; fades by ~2nd month Yolk sac (+ AGM region for definitive HSCs) Primitive erythroblasts โ†’ Gower-1, Gower-2, Portland Hbs Intravascular (inside developing vessels)
Hepatic Starts 5โ€“7 gestational weeks; peak 3rd month; declines after 6th month; minimal until 1โ€“2 wk after birth Liver (major), + spleen, thymus, kidney, lymph nodes, placenta Erythroid, granulocytic, monocytic, megakaryocytic; lymphoid appears; Hb F predominant Extravascular; liver = major site in 2nd trimester; thymus = first fully developed organ (T cells)
Medullary (myeloid) Begins before 5th month; marrow = primary site by end of 24 weeks Bone marrow cavity All lineages; EPO, G-CSF, GM-CSF, Hb F and Hb A measurable M:E ratio approaches adult 3:1

The site moves because each niche offers a different microenvironment. The exam trap: the marrow starts before month 5 but is not the primary site until ~24 weeks.

2.4 Adult Bone Marrow

Feature Details
Definition Tissue in bone cavities, one of the largest organs; trabeculae form a honeycomb supporting blood cell development
Red vs yellow Red = active hematopoietic tissue; yellow = inactive, mostly adipocytes
Distribution Infants: red marrow in all bones. Retrogression begins 5โ€“7 years. Adult red marrow: sternum, vertebrae, scapulae, pelvis, ribs, skull, proximal long bones
Normal values Adult cellularity โ‰ˆ 50% cells / 50% fat (rule of thumb: cellularity โ‰ˆ 100 โˆ’ age); M:E โ‰ˆ 3:1 (2:1โ€“4:1); mitotic index 1โ€“2%
Mechanism of expansion Increased demand (hemolysis, blood loss) โ†’ yellow marrow reconverts to red marrow; if the marrow is failing or fibrosed โ†’ extramedullary hematopoiesis in liver/spleen
Architecture Cells develop in extravascular cords between vascular sinuses. Erythroblasts cluster around iron-laden macrophages (erythroblastic islands) near sinuses; megakaryocytes sit against sinus walls (shed platelets into lumen); immature granulocytes deep in cords, moving toward sinuses as they mature
Release Mature cells pass between adventitial cells, through basement membrane and endothelial pores into sinuses
Daily output ~2.5 billion RBCs, 2.5 billion platelets, 1 billion granulocytes per kg body weight
Clinical significance Best biopsy site in adults: posterior iliac crest (sternum for aspirate only in adults); tibia may be used in infants
๐Ÿงช PRE-ANALYTICAL โ€” Bone marrow aspirate & core biopsy
  • Aspirate: first 0.5โ€“1 mL for smears (less hemodilution); EDTA for smears/flow, heparin for cytogenetics
  • Core: fixed promptly, then decalcified โ€” decalcification damages DNA/antigens, so molecular work prefers the aspirate
  • Dry tap (no aspirate) suggests fibrosis or a packed marrow โ†’ rely on the core biopsy and touch preps
  • Hemodilution falsely lowers cellularity and M:E interpretation โ€” look for marrow spicules

2.5 Spleen

Feature Details
Definition Largest lymphoid organ (LUQ); vital but not essential; indiscriminate blood filter
Zones White pulp (follicles; T cells in the PALS, B cells in nodules/germinal centers) ยท marginal zone (memory B, CD4 T, macrophages) ยท red pulp (sinuses + cords of Billroth with macrophages)
Blood content & flow ~350 mL of blood; receives ~350 mL/min; holds ~30% of the platelet mass
Mechanism of RBC removal Slow transit through cords โ†’ acidic, hypoglycemic, hypoxic environment + narrow inter-endothelial slits โ†’ rigid/old RBCs trapped
Culling vs pitting Culling = whole cell phagocytosed ยท Pitting = inclusions or damaged membrane removed, cell returned
Splenomegaly Chronic leukemias, hemoglobinopathies, thalassemia, membrane/enzyme defects, Hodgkin, malaria, MPNs
Hypersplenism Splenomegaly + cytopenia(s) despite a hyperactive marrow; most common cause: congestive splenomegaly from cirrhosis/portal hypertension
Splenectomy Used in refractory AIHA, severe hereditary spherocytosis, refractory ITP; afterward platelet and WBC counts rise transiently; inclusions (e.g., Howell-Jolly bodies) persist on smear
Sickle cell Repeated infarcts โ†’ autosplenectomy
๐Ÿงช PRE-ANALYTICAL โ€” Peripheral smear for splenic function
  • EDTA blood; make smears within a few hours to avoid storage artifacts (crenation, degenerating WBCs)
  • Distinguish true inclusions (Howell-Jolly, Pappenheimer) from stain precipitate on top of cells
  • A transient post-splenectomy thrombocytosis is expected โ€” interpret platelet counts against surgery date

2.6 Liver, Lymph Nodes, Thymus

Organ Hematopoietic Role Key Zones / Cells Exam Pearl
Liver Major fetal site (2nd trimester); adult source of TPO (and minor EPO); EMH in myelofibrosis Hepatocyte plates, sinusoids, Kupffer cells (macrophages) Storage diseases of Kupffer cells (Gaucher, Niemann-Pick) โ†’ hepatomegaly; porphyrias injure hepatocytes
Lymph nodes Lymphocyte proliferation, immune response, filtration Cortex = follicles (B); paracortex = T; medullary cords = plasma cells Primary follicle = no germinal center; secondary = germinal center (activated B)
Thymus T-cell maturation Cortex: progenitors DN โ†’ DP (CD4+CD8+); medulla: SP mature T cells; Hassall’s corpuscles 12โ€“15 g at birth โ†’ 30โ€“40 g puberty โ†’ 10โ€“15 g later; atrophies. Congenital absence โ†’ no T cells, infections, early death

2.7 Erythropoietin (EPO)

Feature Details
Definition Lineage-specific glycoprotein; the only true endocrine (hormonal) hematopoietic cytokine
Tissue source Adult: renal peritubular interstitial cells (small amount liver). Embryo: mainly liver
Mechanism of elevation Kidney senses reduced Oโ‚‚ delivery (anemia, hypoxia, altitude) โ†’ โ†‘ EPO โ†’ recruits CFU-E from BFU-E, blocks apoptosis of erythroid progenitors, induces Hb synthesis
Target cells CFU-E (many receptors, absolute requirement) > BFU-E (few receptors). Reticulocytes and mature RBCs have no EPO receptors
Receptor / signaling Homodimeric receptor โ†’ JAK2 โ†’ STAT5
Low EPO Chronic kidney disease (anemia of CKD); polycythemia vera (autonomous erythropoiesis suppresses EPO); truncated EPO-R erythrocytosis
High EPO Anemias with intact kidneys, hypoxic states, EPO-secreting tumors (secondary erythrocytosis)
Therapeutic use Anemia of CKD, chemotherapy anemia, HIV/zidovudine anemia, autologous pre-donation, post-transplant
๐Ÿงช PRE-ANALYTICAL โ€” Serum EPO
  • Serum immunoassay; draw before transfusion or ESA therapy โ€” both distort the level
  • Interpret against the hemoglobin: a ‘normal’ EPO in a severely anemic patient is inappropriately low
  • Reference intervals are method-dependent (roughly 4โ€“25 mU/mL) โ€” always use your lab’s range

2.8 Thrombopoietin (TPO) and Myeloid CSFs

Feature Details
TPO (MPL ligand, MGDF) Main source: liver. Major physiologic regulator of megakaryocyte proliferation and platelet production; with IL-11 gives the greatest platelet increase; also maintains quiescent HSCs (TPO-R = CD110 on HSCs)
G-CSF Late-acting, neutrophil lineage (CFU-G); also enhances mature neutrophil function. Uses: chemotherapy neutropenia, congenital/cyclic neutropenia, stem cell mobilization
GM-CSF Multilineage: CFU-GM (neutrophils + monocytes), all lineages except basophils; activates mature phagocytes; synergizes with IL-3 for megakaryocytes
M-CSF Monocyte/macrophage lineage; also osteoclast genesis; receptor has intrinsic tyrosine kinase
IL-5 Eosinophil differentiation (with GM-CSF, IL-3)
IL-3 Early multilineage ‘burst-promoting activity’ โ€” supports BFU-E, granulocytes, monocytes, megakaryocytes, basophils

2.9 Cytokine Classification

Class Members Main Action Exam Hook
Early-acting (multilineage) SCF (KIT ligand), FLT3 ligand, IL-3, GM-CSF, IL-6, IL-11 Bring HSC/progenitors out of G0, prevent apoptosis, expand multiple lineages SCF & FLT3L are mostly membrane-bound โ†’ juxtacrine; neither forms colonies alone
Late-acting (lineage-restricted) EPO, TPO, G-CSF, M-CSF, IL-5; lymphoid ILs (2, 4, 7, 10, 12, 13, 14, 15) Drive differentiation of committed progenitors IL-5 is the odd one out in ‘multilineage EXCEPT’ questions
Indirect-acting IL-1 No colony activity itself; induces accessory cells to release direct-acting factors IL-1 given in vivo โ†’ neutrophilic leukocytosis
Negative regulators TGF-ฮฒ, TNF-ฮฑ, interferons, MIP-1ฮฑ (stem cell inhibitor), PGE, lactoferrin, acidic isoferritins, Di-OH vitamin Dโ‚ƒ, T-suppressor & NK cells Keep HSCs quiescent; limit proliferation (e.g., TGF-ฮฒ โ†‘ p21) SCF is never a negative regulator
Signaling Mode How It Works Example
Autocrine Cell stimulates itself Tumor cells feeding their own growth
Paracrine Secreted, acts on neighbor over short distance Most marrow cytokines
Juxtacrine Membrane-bound; needs direct cellโ€“cell contact SCF, FLT3L, MIP-1ฮฑ from stroma
Endocrine Travels in blood to a distant organ EPO (kidney โ†’ marrow)

2.10 Receptors, Signaling & Disease

Receptor Group Members Clinical Correlation
Intrinsic tyrosine kinase KIT (SCF), FLT3, M-CSF-R FLT3 and KIT mutations appear in myeloid neoplasms
Homodimer, JAK-associated EPO-R, G-CSF-R, TPO-R (MPL) JAK2 V617F โ†’ constitutive JAK2-STAT signaling โ†’ polycythemia vera
Shared ฮฒc chain IL-3, IL-5, GM-CSF Explains overlapping (redundant) activity of IL-3 and GM-CSF
Shared gp130 IL-6, IL-11 Both boost megakaryopoiesis and the acute-phase response
Shared ฮณc chain IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 ฮณc mutation โ†’ X-linked SCID (far worse than IL-2Rฮฑ defect โ€” six cytokines lost)
G-CSF-R (truncated maturation domain) โ€” Kostmann syndrome / severe congenital neutropenia: arrest at promyelocyte/myelocyte
EPO-R (truncated negative domain) โ€” Familial benign erythrocytosis with low EPO (hypersensitive BFU-E/CFU-E)

Most hematopoietic receptors lack their own kinase: ligand binding โ†’ receptor dimerization โ†’ JAK phosphorylation โ†’ STAT docking, dimerization, nuclear translocation โ†’ gene transcription. Growth factors are permissive (survival, proliferation); transcription factors are instructive (lineage choice) โ€” and many are disrupted by leukemia translocations.

2.11 Microenvironment (Niche)

Component Members Function
Stromal cells Adipocytes, endothelial cells, fibroblasts/reticular adventitial cells, macrophages, T cells, osteoblasts Produce soluble and membrane-bound cytokines, homing receptors, ECM
Extracellular matrix Collagen, fibronectin, laminin, thrombospondin, hemonectin, glycosaminoglycans (heparan, chondroitin, dermatan sulfate) Structural support; binds cytokines near target cells
Fibronectin Receptor on HSC/PC and erythroblasts Retains erythroid cells; lost at reticulocyte stage โ†’ release
Hemonectin Receptor on HSC/PC and granulocytes Retains granulocytic cells; loss โ†’ release of mature granulocytes
CXCL12 (SDF-1) / CXCR4 Stroma ligand / HSC receptor Holds HSC in niche; blocked by plerixafor for mobilization

2.12 General Morphologic Changes of Maturation

Structure Immature (blast) Mature
Cell size Large โ†“ Smaller
N:C ratio High โ†“ Lower (more cytoplasm)
Nucleoli Present Lost
Chromatin Fine, open Condensed, clumped
Nucleus Round, large โ†“ Size; may change shape (segments) or be lost (RBC)
Cytoplasm Deep blue (basophilic, RNA-rich) โ†“ Basophilia; granules may appear

3 ยท Visual Memory Hooks

๐Ÿง  Sites in order
โ€œYour Liver Makes Bloodโ€ โ†’ Yolk sac โ†’ Liver โ†’ Marrow (Bone). Liver = the 2nd-trimester boss.
๐Ÿง  Embryonic hemoglobins
โ€œGrandpa Gower Gower moved to Portlandโ€ โ†’ Gower-1, Gower-2, Portland = yolk sac. Hepatic phase = Hb F (Fetal).
๐Ÿง  Adult red marrow sites
โ€œSome Very Smart People Remember Special Placesโ€ โ†’ Sternum, Vertebrae, Skull, Pelvis, Ribs, Scapulae, Proximal long bones. Biopsy: Pelvis (posterior iliac crest).
๐Ÿง  HSC phenotype
โ€œ34 in, 38 out, DR out, Lin out, dye outโ€ โ†’ CD34+, CD38โˆ’, HLA-DRโˆ’, Linโˆ’, Rh123 dull.
๐Ÿง  Erythroid progenitors
BFU-E = Before, Big bursts, Barely EPO-sensitive. CFU-E = Close to the pronormoblast, Craves EPO.
๐Ÿง  EPO vs TPO sources
โ€œK-EPO, L-TPOโ€ โ†’ Kidney makes EPO; Liver makes TPO.
๐Ÿง  Early-acting cytokines
โ€œSuper Fast Starters: 3, GM, 6, 11โ€ โ†’ SCF, FLT3L, IL-3, GM-CSF, IL-6, IL-11.
๐Ÿง  Shared receptor chains
ฮฒc = 3-5-GM ยท gp130 = 6 & 11 ยท ฮณc = 2-4-7-9-15-21 (ฮณc down โ†’ SCID).
๐Ÿง  Negative regulators
โ€œTiny Tigers In My Pet Labโ€ โ†’ TNF-ฮฑ, TGF-ฮฒ, IFNs, MIP-1ฮฑ, PGE, Lactoferrin/isoferritins.
๐Ÿง  Spleen
Culling Kills the whole cell ยท Pitting Picks out the inclusion. ~โ…“ of platelets live in the spleen.
๐Ÿง  Lymph node
โ€œB outside, T in between, Plasma in the middleโ€ โ†’ cortex, paracortex, medulla.
๐Ÿง  Thymus
โ€œCortex Doubles, Medulla Singlesโ€ โ†’ DN enters โ†’ DP in cortex โ†’ SP in medulla.
๐Ÿง  Signaling
Auto = selfie ยท Para = neighbor ยท Juxta = handshake (membrane-bound SCF/FLT3L) ยท Endo = mail by blood (EPO).
๐Ÿง  Maturation
โ€œSmaller, Tighter, Paler, No nucleoliโ€ โ†’ smaller cell, condensed chromatin, less basophilic cytoplasm, nucleoli gone.

Pattern Triggers

If you seeโ€ฆ Thinkโ€ฆ Becauseโ€ฆ
Pancytopenia + big spleen + hypercellular marrow Hypersplenism Spleen sequesters and destroys cells the marrow is actively making
Howell-Jolly bodies + thrombocytosis after surgery Post-splenectomy Pitting lost; the 30% platelet pool is released
Erythrocytosis + low EPO + JAK2 V617F Polycythemia vera Constitutive JAK2-STAT signaling makes EPO unnecessary
Erythrocytosis + low EPO + family history, JAK2 negative Truncated EPO receptor Loss of the negative-control domain โ†’ hypersensitivity to EPO
Erythrocytosis + high EPO Secondary (hypoxia, smoking, altitude, EPO tumor) Normal kidney response or ectopic EPO
Anemia of CKD with low reticulocytes EPO deficiency Peritubular interstitial cells lost
Infant, recurrent infections, no T or NK cells, X-linked ฮณc chain defect (X-SCID) Six ฮณc cytokines, including IL-7 and IL-15, fail
Profound neutropenia, marrow arrested at promyelocytes Kostmann (G-CSF-R defect) Proliferation domain intact, maturation domain lost
Teardrop cells + leukoerythroblastosis + hepatosplenomegaly Myelofibrosis with EMH Fibrotic marrow pushes hematopoiesis to liver/spleen
Elevated mitotic index in B12/folate deficiency Prolonged mitosis, not true proliferation Megaloblastic anemia is the classic exception

Commonly Confused Pairs

Feature A B
BFU-E vs CFU-E More primitive; large bursts at ~14 days; few EPO-R; needs IL-3/GM-CSF (BPA) More mature; small colonies at 7โ€“8 days; many EPO-R; absolute EPO need
EPO vs TPO Kidney (peritubular interstitial cells); hypoxia-driven; erythroid Liver; megakaryocytes/platelets; also HSC maintenance
Culling vs pitting Whole RBC destroyed Inclusion removed, RBC returned
Stem vs progenitor Self-renews; pluripotent; ~0.5% No self-renewal; restricted; ~3%
Paracrine vs juxtacrine Secreted to neighbor Membrane-bound, needs contact
Stochastic vs instructive model Self-renew/differentiate decision is random Microenvironment directs the decision (current view: both)
Fibronectin vs hemonectin Retains erythroid cells Retains granulocytic cells
Hypersplenism vs aplastic anemia Cytopenias + hypercellular marrow + splenomegaly Cytopenias + hypocellular marrow

Diagnostic Window / Timeline Table

Marker / Site Onset Peak Duration / End Best Exam Use
Yolk sac hematopoiesis ~Day 19 Weeks 3โ€“6 Disappears during hepatic phase (~2nd month) Embryonic Hbs (Gower-1, Gower-2, Portland)
Fetal liver 5โ€“7 gestational weeks 3rd month Declines after 6th month; minimal until 1โ€“2 weeks after birth Primary site in 2nd trimester; Hb F
Bone marrow Before 5th month Primary site from 24 weeks Lifelong Adult M:E 3:1
Red โ†’ yellow marrow (retrogression) 5โ€“7 years Adulthood Adult ~50% fat in active sites Biopsy site by age
Thymus weight 12โ€“15 g at birth 30โ€“40 g at puberty 10โ€“15 g later; atrophic in old age T-cell production capacity
BFU-E colony (culture) โ€” ~14 days โ€” More primitive erythroid progenitor
CFU-E colony (culture) โ€” 7โ€“8 days โ€” EPO-dependent progenitor
Post-splenectomy counts Days Transient Platelets/WBC return toward baseline Expected thrombocytosis, not pathology

4 ยท Diagnostic Flowcharts

Flowchart 1 โ€” Pancytopenia: marrow failure or peripheral loss?

Adult with pancytopenia โ†’ Check spleen size and perform marrow biopsy
Marrow hypocellular, no infiltrate โ†’ Marrow failure (e.g., aplastic anemia) โ†’ HSC injury
Marrow hypercellular + splenomegaly + cirrhosis/portal HTN โ†’ Hypersplenism โ†’ splenic sequestration/destruction
Dry tap, fibrosis, teardrops, leukoerythroblastosis, hepatosplenomegaly โ†’ Myelofibrosis / myelophthisis with extramedullary hematopoiesis
Hypercellular marrow with megaloblasts, high mitotic index โ†’ Megaloblastic anemia (ineffective hematopoiesis, prolonged mitosis)
โš ๏ธ Common mistake: equating pancytopenia with marrow failure. In hypersplenism the marrow is working harder, not less.

Flowchart 2 โ€” Where is blood being made? (age / gestational timing)

Embryo < ~6 weeks โ†’ Yolk sac (intravascular) + AGM โ†’ Gower-1, Gower-2, Portland
Fetus 2nd trimester (months 3โ€“6) โ†’ Liver is primary (peak month 3); spleen, thymus contribute; Hb F
Fetus โ‰ฅ 24 weeks โ†’ birth โ†’ Bone marrow primary; all bones red at birth
Child 5โ€“7 years onward โ†’ Retrogression begins in long-bone shafts
Adult biopsy needed โ†’ Posterior iliac crest (axial skeleton / pelvis)
โš ๏ธ Common mistake: answering ‘bone marrow’ for a 4โ€“5-month fetus. Marrow activity begins before month 5 but the liver still dominates until ~24 weeks.

Flowchart 3 โ€” Choosing the method to study a precursor

Need to identify a precursor โ†’ Is it morphologically recognizable?
Yes (โ€“blasts, โ€“cytes) โ†’ Wright-Giemsa morphology: differential, M:E ratio, cellularity on core
No โ€” need a number for transplant โ†’ Flow cytometry CD34+ enumeration (viability dye, standardized gating)
No โ€” need proof of function/lineage potential โ†’ Colony assays in methylcellulose (CFU-GEMM, CFU-GM, BFU-E); LTC-IC for primitive cells
Need proof of true long-term stemness โ†’ In-vivo serial transplantation into irradiated recipients
โš ๏ธ Common mistake: treating a CD34 count as a pure stem cell count. CD34 also marks early progenitors; only repopulation proves stemness.

Flowchart 4 โ€” Erythrocytosis work-up using EPO

Confirmed โ†‘ Hct/Hb โ†’ Measure serum EPO (before therapy)
EPO high/normal-high โ†’ Secondary: hypoxia, smoking, altitude, EPO-secreting tumor
EPO low + JAK2 V617F (ยฑ โ†‘ WBC, โ†‘ PLT, splenomegaly) โ†’ Polycythemia vera
EPO low + JAK2 negative + family history, isolated erythrocytosis โ†’ Familial erythrocytosis (truncated EPO-R)
โš ๏ธ Common mistake: assuming every low-EPO erythrocytosis is PV. A truncated EPO receptor also gives low EPO โ€” but it is inherited, benign, and JAK2-negative.

Flowchart 5 โ€” Selecting growth factor therapy

Anemia of chronic kidney disease โ†’ Recombinant EPO (acts on CFU-E; ensure iron is adequate)
Chemotherapy-induced neutropenia โ†’ G-CSF (or GM-CSF)
Chemotherapy thrombocytopenia โ†’ IL-11 (TPO pathway agents)
Collect stem cells from donor blood โ†’ G-CSF ยฑ plerixafor (CXCR4 antagonist) โ†’ apheresis
Hairy cell leukemia / CML / Kaposi (historic) โ†’ IFN-ฮฑ
โš ๏ธ Common mistake: expecting EPO to act on reticulocytes or mature RBCs โ€” they have no EPO receptors; the response comes from CFU-E days later.

5 ยท 25 High-Yield Facts

# Fact
1 Hematopoiesis begins around day 19 of embryonic development in the yolk sac.
2 Yolk sac hematopoiesis is intravascular and produces Gower-1, Gower-2, and Portland hemoglobins.
3 The AGM (aorta-gonad-mesonephros) region gives rise to definitive HSCs.
4 The liver is the primary site of hematopoiesis during the second trimester, peaking at the third month.
5 Hb F is the predominant hemoglobin of the hepatic phase.
6 The thymus is the first fully developed fetal organ and the main site of T-cell production.
7 The bone marrow becomes the primary site by the end of 24 weeks’ gestation.
8 Retrogression (red โ†’ yellow marrow) begins at 5โ€“7 years of age.
9 Adult active marrow: sternum, vertebrae, scapulae, pelvis, ribs, skull, proximal long bones.
10 The best marrow biopsy site in adults is the posterior iliac crest.
11 Normal adult marrow is about 50% cells and 50% fat, with an M:E ratio of about 3:1.
12 Erythroblasts surround iron-laden macrophages; megakaryocytes sit against sinus walls.
13 The spleen holds about 30% of the platelet mass.
14 Culling removes whole cells; pitting removes inclusions and returns the cell.
15 Hypersplenism is cytopenia despite a hyperactive marrow, most often from portal hypertension.
16 HSC phenotype: CD34+, CD38โˆ’, HLA-DRโˆ’, Thy-1 low, Linโˆ’, Rhodamine-123 dull.
17 Stem cells โ‰ˆ 0.5%, progenitors โ‰ˆ 3%, maturing cells > 95% of marrow precursors.
18 IL-7 receptor distinguishes the common lymphoid progenitor from the common myeloid progenitor.
19 CFU-E is the progenitor most sensitive to EPO; BFU-E has few EPO receptors.
20 EPO is made by renal peritubular interstitial cells in response to hypoxia.
21 TPO is made mainly by the liver; TPO and IL-11 give the greatest rise in platelets.
22 Early-acting cytokines: SCF, FLT3L, IL-3, GM-CSF, IL-6, IL-11; IL-5 is lineage-restricted (eosinophils).
23 IL-3, IL-5, and GM-CSF share the ฮฒc chain; IL-6 and IL-11 share gp130.
24 A ฮณc chain defect causes X-linked SCID; JAK2-STAT abnormalities cause polycythemia vera.
25 Maturation brings smaller cells, lower N:C ratio, loss of nucleoli, condensed chromatin, and less basophilic cytoplasm.
โญ EXAM TIP โ€” The single most testable pattern

Match the step to the factor: EPO โ†’ CFU-E (kidney) ยท TPO โ†’ megakaryocytes (liver) ยท G-CSF โ†’ neutrophils ยท M-CSF โ†’ monocytes ยท IL-5 โ†’ eosinophils. When a question says ‘EXCEPT’ among early-acting cytokines, the answer is the lineage-restricted one โ€” usually IL-5.

Quick Interpretation Table

Lab Finding Clinical Interpretation
Pancytopenia + hypercellular marrow + splenomegaly Hypersplenism
Low EPO + erythrocytosis + JAK2 V617F Polycythemia vera
Low EPO + normocytic anemia + โ†‘ creatinine Anemia of chronic kidney disease
Howell-Jolly bodies + โ†‘ platelets Post-splenectomy / asplenia
Teardrop cells + nucleated RBCs + immature granulocytes Marrow fibrosis/infiltration with extramedullary hematopoiesis
Adult marrow cellularity ~90% at age 60 Hypercellular โ€” reactive or neoplastic process
Rising CD34+ count in donor blood after G-CSF ยฑ plerixafor Successful mobilization โ€” ready for apheresis

๐ŸŽด Flashcards โ€” Active Recall Practice

How it works: tap the card to flip it. Then mark it โœ“ Knew It or โœ— Review Again (buttons unlock after flipping). Use ๐Ÿ”€ Shuffle to randomize and ๐Ÿ Finish anytime โ€” your summary appears at the end, and you can drill only the cards you missed.

๐Ÿ“ Practice Quiz โ€” Test Your Knowledge

How it works: tap an answer for each case. You’ll get instant feedback with the full explanation and the examiner’s trap. Your final score appears once all 10 are answered.

๐Ÿชค Trap Questions โ€” Beat the Examiner

Harder on purpose. Each question targets a real misconception. After answering you’ll see the correct reasoning, the trap explained, why the examiner wrote it, and the wrong answer most students choose.

8 ยท Rapid Revision Sheet

๐Ÿ“– READ THIS 2 HOURS BEFORE YOUR EXAM

Development Timeline

  • Start: day 19, yolk sac
  • Yolk sac: Gower-1, Gower-2, Portland ยท intravascular
  • Liver: 5โ€“7 wk โ†’ peak month 3 โ†’ 2nd trimester boss ยท Hb F
  • Marrow: starts < month 5 ยท primary at 24 wk
  • Thymus = first fully developed organ

Adult Marrow Numbers

  • Cellularity โ‰ˆ 50/50 (โ‰ˆ100 โˆ’ age)
  • M:E โ‰ˆ 3:1
  • Mitotic index 1โ€“2%
  • Retrogression 5โ€“7 y
  • Biopsy: posterior iliac crest
  • Sites: sternum, vertebrae, skull, pelvis, ribs, scapulae, proximal long bones

HSC & Compartments

  • HSC: CD34+ CD38โˆ’ HLA-DRโˆ’ Thy-1lo Linโˆ’ Rh123dull, CD117+ CD110+
  • Stem 0.5% ยท progenitor 3% ยท maturing >95%
  • CLP = IL-7R+ ยท CMP = IL-7Rโˆ’
  • Myeloid commit: CD33 + CD38 ยท lymphoid: CD10 + CD38

Erythroid & Sources

  • BFU-E: primitive, 14-day bursts, few EPO-R
  • CFU-E: 7โ€“8 days, many EPO-R, EPO-dependent
  • EPO = kidney (peritubular interstitial) ยท hypoxia
  • TPO = liver ยท TPO + IL-11 โ†’ max platelets
  • Retics/RBCs: no EPO-R

Cytokine Pairs

  • Early: SCF, FLT3L, IL-3, GM-CSF, IL-6, IL-11
  • Late: EPO, TPO, G-CSF, M-CSF, IL-5
  • Indirect: IL-1
  • ฮฒc: IL-3/5/GM ยท gp130: IL-6/11 ยท ฮณc: IL-2/4/7/9/15/21
  • Negative: TGF-ฮฒ, TNF-ฮฑ, IFN, MIP-1ฮฑ, PGE, lactoferrin

Spleen

  • Culling = whole cell ยท Pitting = inclusion
  • ~30% platelets ยท ~350 mL blood
  • Hypersplenism: cytopenia + HYPERcellular marrow
  • Post-splenectomy: โ†‘ PLT, โ†‘ WBC (transient), H-J bodies
  • Sickle cell โ†’ autosplenectomy

Opposites

  • Maturation โ†“: size, N:C, basophilia, nucleoli
  • Maturation โ†‘: chromatin condensation, granules
  • PV: โ†“ EPO ยท secondary erythrocytosis: โ†‘ EPO
  • Aplastic: hypocellular ยท hypersplenism: hypercellular

Lymphoid Organs

  • Node: cortex B ยท paracortex T ยท medulla plasma cells
  • Primary follicle: no germinal center
  • Spleen PALS = T
  • Thymus: DN โ†’ DP (cortex) โ†’ SP (medulla)
  • 12โ€“15 g โ†’ 30โ€“40 g โ†’ 10โ€“15 g

Confusing Pairs

  • Paracrine (secreted) vs juxtacrine (membrane-bound)
  • Fibronectin โ†’ erythroid ยท hemonectin โ†’ granulocytic
  • ฮณc defect (SCID) > IL-2Rฮฑ defect
  • JAK2 PV vs truncated EPO-R (both low EPO)
  • โ†‘ mitotic index โ‰  โ†‘ proliferation in megaloblastic

Clinical Growth Factors

  • EPO โ†’ anemia of CKD
  • G-CSF โ†’ chemo neutropenia, mobilization
  • Plerixafor โ†’ CXCR4 antagonist
  • IL-11 โ†’ thrombocytopenia
  • IFN-ฮฑ โ†’ hairy cell, CML, Kaposi ยท IL-2 โ†’ RCC, melanoma
  • Kostmann โ†’ G-CSF-R, promyelocyte arrest

9 ยท Final Memory Map

  • ๐Ÿฉธ HEMATOPOIESIS
    • Development
      • Yolk sac (day 19, intravascular, Gower/Portland)
      • Liver (5โ€“7 wk, peak month 3, Hb F)
      • Marrow (primary at 24 wk, M:E โ†’ 3:1)
    • Adult Tissues
      • Marrow: 50% fat, axial skeleton, biopsy iliac crest
      • Spleen: culling, pitting, 30% platelets, hypersplenism
      • Liver: TPO, Kupffer cells, EMH
      • Node: B cortex / T paracortex / plasma medulla
      • Thymus: DN โ†’ DP โ†’ SP
    • Cell Hierarchy
      • HSC 0.5%: CD34+ CD38โˆ’ HLA-DRโˆ’ Linโˆ’ Rh123 dull
      • Progenitors 3%: CLP (IL-7R+) / CMP โ†’ CFU-GEMM
      • BFU-E โ†’ CFU-E โ†’ pronormoblast
      • Maturing cells >95%: recognizable
    • Cytokines
      • Early: SCF, FLT3L, IL-3, GM-CSF, IL-6, IL-11
      • Late: EPO (kidney), TPO (liver), G-CSF, M-CSF, IL-5
      • Indirect: IL-1 ยท Negative: TGF-ฮฒ, TNF-ฮฑ, IFN, MIP-1ฮฑ
      • Juxtacrine: SCF, FLT3L ยท Endocrine: EPO
    • Receptors & Disease
      • ฮฒc: IL-3/5/GM ยท gp130: IL-6/11
      • ฮณc โ†’ X-SCID
      • JAK2-STAT โ†’ polycythemia vera
      • G-CSF-R โ†’ Kostmann ยท truncated EPO-R โ†’ familial erythrocytosis
    • Niche & Therapy
      • Stroma + ECM; fibronectin (RBC), hemonectin (granulocytes)
      • CXCL12/CXCR4 โ†’ plerixafor mobilization
      • EPO, G-CSF, GM-CSF, IL-11, IFN-ฮฑ, IL-2 in clinic
    • Maturation
      • โ†“ size, โ†“ N:C, โ†“ basophilia, nucleoli lost
      • Chromatin condenses; granules appear; RBC loses nucleus



PreviousNext